AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

TransMedics Group Inc

Healthcare US TMDX

134.95USD
-1.19(0.87%)

Last update at 2024-05-16T16:50:00Z

Day Range

133.62136.04
LowHigh

52 Week Range

36.4299.63
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.16500M -44.17900M -28.71600M -33.50700M -23.71500M
Minority interest - - - - -
Net income -36.23100M -44.21500M -28.74800M -33.54700M -23.75600M
Selling general administrative 51.69M 38.28M 24.19M 23.60M 12.31M
Selling and marketing expenses 18.21M - 0.93M - 1.02M
Gross profit 65.27M 21.16M 16.64M 13.86M 5.73M
Reconciled depreciation 3.48M 1.82M 1.58M 1.22M 0.77M
Ebit -31.43700M -39.42800M -26.38400M -29.60300M -20.45000M
Ebitda -32.43900M -40.30500M -24.73100M -28.81300M -19.68100M
Depreciation and amortization -1.00200M -0.87700M 1.65M 0.79M 0.77M
Non operating income net other - -0.87700M - - -
Operating income -31.43700M -39.42800M -26.38400M -29.60300M -20.23700M
Other operating expenses 124.90M 69.69M 52.02M 53.21M 33.25M
Interest expense 3.73M 3.87M 3.98M 4.35M 2.72M
Tax provision 0.07M 0.04M 0.03M 0.04M 0.04M
Interest income - - - - -
Net interest income -3.72600M -3.87400M -3.98500M -4.35300M -2.72000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.04M 0.03M 0.04M 0.04M
Total revenue 93.46M 30.26M 25.64M 23.60M 13.02M
Total operating expenses 96.71M 60.59M 43.02M 43.47M 25.97M
Cost of revenue 28.19M 9.10M 9.00M 9.74M 7.28M
Total other income expense net -4.72800M -4.75100M -2.33200M -3.90400M -0.75800M
Discontinued operations - - - - -
Net income from continuing ops -36.23100M -44.21500M -28.71600M -33.54700M -23.75600M
Net income applicable to common shares -36.23100M -44.21500M -28.74800M -33.54700M -23.75600M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 277.15M 134.89M 152.03M 105.30M 42.16M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.90M 5.46M 2.33M 1.54M 1.84M
Total liab 89.77M 67.04M 48.13M 50.65M 46.98M
Total stockholder equity 187.38M 67.85M 103.89M 54.65M -4.82500M
Deferred long term liab - - 1.60M - 3.38M
Other current liab 18.64M 16.34M 10.41M 8.70M 7.53M
Common stock 666.28M 510.49M 502.22M 424.13M 331.21M
Capital stock 666.28M 510.49M 502.22M 424.13M 331.21M
Retained earnings -478.67700M -442.44600M -398.23100M -369.48300M -335.93600M
Other liab - - 1.60M 0.39M 0.76M
Good will - - - - -
Other assets 0.50M 0.50M 0.51M 0.51M 3.89M
Cash 201.18M 25.58M 24.58M 20.09M 20.24M
Cash and equivalents - - - - -
Total current liabilities 23.66M 23.24M 11.88M 16.11M 12.55M
Current deferred revenue 0.24M 0.25M 0.26M 0.17M 0.31M
Net debt -133.62700M -16.97600M 10.08M 14.05M 13.43M
Short term debt 1.44M 8.60M - - -
Short long term debt - - - - -
Short long term debt total 67.56M 8.60M 34.66M 34.15M 33.67M
Other stockholder equity -0.22500M 68.04M -0.09500M -105.29900M -0.10100M
Property plant equipment 24.35M 15.69M 4.75M 4.79M 3.47M
Total current assets 252.29M 118.70M 146.77M 100.00M 34.79M
Long term investments - - - - -
Net tangible assets 187.38M 67.85M 103.89M 54.65M -192.24200M
Short term investments 0.00000M 66.87M 101.06M 60.60M 0.00000M
Net receivables 27.61M 5.93M 6.86M 6.56M 3.44M
Long term debt 58.70M 35.20M 34.66M 34.15M 33.67M
Inventory 20.61M 14.86M 11.93M 11.22M 9.28M
Accounts payable 3.34M 6.65M 1.21M 7.25M 4.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.22500M -0.18800M -0.09500M -0.00200M -0.10100M
Additional paid in capital - - - - -
Common stock total equity - 510.49M 502.22M 424.13M 331.21M
Preferred stock total equity - - - - -
Retained earnings total equity - -442.44600M -398.23100M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.50M 0.50M 0.51M 0.51M 3.89M
Deferred long term asset charges - - - - -
Non current assets total 24.85M 16.19M 5.26M 5.30M 7.36M
Capital lease obligations 8.86M 8.60M - - -
Long term debt total - 35.20M 34.66M 34.15M 33.67M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 54.51M 32.79M -41.14300M -60.50100M 12.72M
Change to liabilities -3.27000M 9.96M -5.74200M 3.31M 0.23M
Total cashflows from investing activities 54.51M 29.27M -41.59800M -60.50100M 12.31M
Net borrowings 22.46M 22.46M 22.46M 22.46M 24.36M
Total cash from financing activities 167.93M 1.39M 75.55M 92.72M 22.06M
Change to operating activities 6.21M 1.96M 2.11M 2.35M 0.65M
Net income -36.23100M -44.21500M -28.74800M -33.54700M -23.75600M
Change in cash 175.60M 1.00M 4.49M -0.14900M 8.30M
Begin period cash flow 26.08M 25.08M 20.59M 20.74M 12.44M
End period cash flow 201.68M 26.08M 25.08M 20.59M 20.74M
Total cash from operating activities -45.81700M -28.86400M -30.26500M -32.28600M -25.98400M
Issuance of capital stock 139.85M 0.00000M 75.67M 97.37M 0.00000M
Depreciation 3.48M 1.82M 1.58M 1.22M 0.77M
Other cashflows from investing activities - - - -60.33600M 12.72M
Dividends paid - - -0.35700M - -
Change to inventory -8.02400M -4.89400M -1.74000M -4.12100M -2.69900M
Change to account receivables -21.67800M 0.84M -0.21800M -3.16600M -2.51300M
Sale purchase of stock 0.51M 0.42M 0.36M 0.20M 0.05M
Other cashflows from financing activities 63.61M 0.97M 2.13M -4.64400M 31.14M
Change to netincome 13.70M 7.81M 2.49M 1.67M 1.33M
Capital expenditures 11.91M 3.52M 0.46M 0.17M 0.42M
Change receivables - 0.84M - - -
Cash flows other operating - -1.53900M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 1.80M - - -
Change in working capital -26.75900M 3.00M -5.58800M -1.62600M -4.32700M
Stock based compensation 10.32M 6.88M 2.41M 0.85M 0.14M
Other non cash items 3.37M 1.37M 0.51M 0.47M 0.18M
Free cash flow -57.72400M -32.38300M -30.72000M -32.45100M -26.40200M

Fundamentals

  • Previous Close 136.14
  • Market Cap2565.78M
  • Volume238333
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.04000M
  • Revenue TTM191.82M
  • Revenue Per Share TTM5.93
  • Gross Profit TTM 65.27M
  • Diluted EPS TTM-1.09

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TMDX
TransMedics Group Inc
-1.19 0.87% 134.95 - 263.16 13.14 19.94 13.61 -112.5695
ABT
Abbott Laboratories
0.46 0.44% 105.05 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
2.14 0.64% 334.13 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.43 0.51% 85.15 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
-0.185 0.25% 74.27 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc

200 Minuteman Road, Andover, MA, United States, 01810

Key Executives

Name Title Year Born
Dr. Waleed H. Hassanein M.D. Founder, Pres, MD, CEO & Director 1968
Mr. Stephen Gordon CFO. Treasurer & Sec. 1968
Dr. Tamer I. Khayal M.D. Chief Commercial Officer 1969
Ms. Miriam C. Provost Ph.D. VP of Global Regulatory Affairs NA
Ms. Laura Damme VP of Clinical Affairs NA
Mr. John F. Carey VP of Operations 1965
Mr. Mark Anderson Sr. Director of Technology Devel. NA
Ms. Susan Goodman VP of HR NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).